



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	09/720,647
Filing Date	July 17, 2001
First Named Inventor	Ramachandran Murali
Group Art Unit	4644-1691
Examiner Name	Kevin E. Weddington
Attorney Docket Number	4040/OL566-USO

RECEIVED
NOV 13 2002
TECH CENTER 1600/2900**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
col	1.	US- 5,597,719	01-28-1997	Freed et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
col	2.	BANNER et al., (1993) Crystal Structure of the Soluble Human 55kd TNF Receptor-Human TNF β Complex: Implications for TNF Receptor Activation, <i>Cell</i> , 73:431-445	
	3.	BERTHOLD et al., (1997) Modes of Peptide Binding in G Protein-Coupled Receptors, <i>Neurochemical Res.</i> , 22:1023-1031	
	4.	BÖHM et al., (1993) A Novel Computational Tool for Automated Structure-based Drug Design, <i>J. of Molecular Recognition</i> , 6:131-137	
	5.	BOTEJU et al., (1996) The Use of Topographical Constraints In Receptor Mapping: Investigation of the Topographical Requirements of the Tryptophan 30 Residue for Receptor Binding of Asp-Tyr-D-Phe-Gly-Trp-(N- Me)Nle-Asp-Phe-NH ₂ (SNF 9007), a Cholecystokinin (28-33) Analogue That Binds to both CCK-B and δ -Opioid Receptors, <i>J. Med. Chem.</i> , 39:4120-4124	
	6.	CHO et al., (1996) Macromolecular versus small-molecule therapeutics: drug discovery, development and clinical considerations, <i>Tibtech</i> , 14:153-159	
	7.	CONNOLLY et al., (1993) The molecular surface package, <i>J. Mol. Graphics</i> , 11:139-141	
	8.	D'AQUINO et al., (1996) The Magnitude of the Backbone Conformational Entropy Change in Protein Folding, <i>Proteins</i> , 25:143-156	
	9.	DESJARLAIS et al., (1986) Docking Flexible Ligands to Macromolecular Receptors by Molecular Shape, <i>J. Med. Chem.</i> , 29:2149-2153	
	10.	DESJARLAIS et al., (1988) Using Shape Complementarity as an Initial Screen in Designing Ligands for a Receptor Binding Site of Known Three-Dimensional Structure, <i>J. Med. Chem.</i> , 31:722-729	

Examiner
SignatureDate
Considered

3/04/03

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.